These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37992000)

  • 1. Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults.
    Athan E; Baber J; Quan K; Scott RJ; Jaques A; Jiang Q; Li W; Cooper D; Cutler MW; Kalinina EV; Anderson AS; Swanson KA; Gruber WC; Gurtman A; Schmoele-Thoma B;
    Clin Infect Dis; 2024 May; 78(5):1360-1368. PubMed ID: 37992000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    Falsey AR; Walsh EE; Scott DA; Gurtman A; Zareba A; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Jiang Q; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Jun; 225(12):2056-2066. PubMed ID: 34931667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    Sadoff J; De Paepe E; Haazen W; Omoruyi E; Bastian AR; Comeaux C; Heijnen E; Strout C; Schuitemaker H; Callendret B
    J Infect Dis; 2021 Feb; 223(4):699-708. PubMed ID: 32851411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
    Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults.
    Murdoch L; Quan K; Baber JA; Ho AWY; Zhang Y; Xu X; Lu C; Cooper D; Koury K; Lockhart SP; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    Infect Dis Ther; 2023 Sep; 12(9):2241-2258. PubMed ID: 37698774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    Baber J; Arya M; Moodley Y; Jaques A; Jiang Q; Swanson KA; Cooper D; Maddur MS; Loschko J; Gurtman A; Jansen KU; Gruber WC; Dormitzer PR; Schmoele-Thoma B
    J Infect Dis; 2022 Dec; 226(12):2054-2063. PubMed ID: 35543281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.
    Buynak R; Cannon K; DeAtkine D; Kirby J; Usdan L; Bhavsar A; Gérard C; Kuznetsova A; Jayadev A; Amare H; Valenciano S; Meyer N
    Infect Dis Ther; 2024 Aug; 13(8):1789-1805. PubMed ID: 38981954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    Peterson JT; Zareba AM; Fitz-Patrick D; Essink BJ; Scott DA; Swanson KA; Chelani D; Radley D; Cooper D; Jansen KU; Dormitzer PR; Gruber WC; Gurtman A
    J Infect Dis; 2022 Jun; 225(12):2077-2086. PubMed ID: 34637519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
    Schwarz TF; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V
    J Infect Dis; 2024 Jul; 230(1):e102-e110. PubMed ID: 39052726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    Simões EAF; Center KJ; Tita ATN; Swanson KA; Radley D; Houghton J; McGrory SB; Gomme E; Anderson M; Roberts JP; Scott DA; Jansen KU; Gruber WC; Dormitzer PR; Gurtman AC
    N Engl J Med; 2022 Apr; 386(17):1615-1626. PubMed ID: 35476650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
    Falloon J; Talbot HK; Curtis C; Ervin J; Krieger D; Dubovsky F; Takas T; Yu J; Yu L; Lambert SL; Villafana T; Esser MT
    Clin Vaccine Immunol; 2017 Sep; 24(9):. PubMed ID: 28679495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    Walsh EE; Falsey AR; Scott DA; Gurtman A; Zareba AM; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Radley D; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Apr; 225(8):1357-1366. PubMed ID: 34932102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
    Walsh EE; Pérez Marc G; Zareba AM; Falsey AR; Jiang Q; Patton M; Polack FP; Llapur C; Doreski PA; Ilangovan K; Rämet M; Fukushima Y; Hussen N; Bont LJ; Cardona J; DeHaan E; Castillo Villa G; Ingilizova M; Eiras D; Mikati T; Shah RN; Schneider K; Cooper D; Koury K; Lino MM; Anderson AS; Jansen KU; Swanson KA; Gurtman A; Gruber WC; Schmoele-Thoma B;
    N Engl J Med; 2023 Apr; 388(16):1465-1477. PubMed ID: 37018468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    Schmoele-Thoma B; Zareba AM; Jiang Q; Maddur MS; Danaf R; Mann A; Eze K; Fok-Seang J; Kabir G; Catchpole A; Scott DA; Gurtman AC; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA
    N Engl J Med; 2022 Jun; 386(25):2377-2386. PubMed ID: 35731653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
    Beran J; Lickliter JD; Schwarz TF; Johnson C; Chu L; Domachowske JB; Van Damme P; Withanage K; Fissette LA; David MP; Maleux K; Schmidt AC; Picciolato M; Dieussaert I
    J Infect Dis; 2018 Apr; 217(10):1616-1625. PubMed ID: 29401325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults.
    Anh DD; Thiem VD; Anh NTH; Huong VM; Nga NT; Thang TC; Thai DH; Chien VC; Holt R; Wahid R; Flores J; Berlanda Scorza F; Taylor DN
    Vaccine; 2016 Oct; 34(45):5457-5462. PubMed ID: 27567493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
    Falsey AR; Williams K; Gymnopoulou E; Bart S; Ervin J; Bastian AR; Menten J; De Paepe E; Vandenberghe S; Chan EKH; Sadoff J; Douoguih M; Callendret B; Comeaux CA; Heijnen E;
    N Engl J Med; 2023 Feb; 388(7):609-620. PubMed ID: 36791161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.